| Literature DB >> 28445442 |
Mengchuan Wang1, Jinrong Zhang2, Shan He3, Xiaojun Yan4.
Abstract
Cyanobacteria are rich sources of structurally-diverse molecules with promising pharmacological activities. Marine cyanobacteria have been proven to be true producers of some significant bioactive metabolites from marine invertebrates. Macrolides are a class of bioactive compounds isolated from marine organisms, including marine microorganisms in particular. The structural characteristics of macrolides from cyanobacteria mainly manifest in the diversity of carbon skeletons, complexes of chlorinated thiazole-containing molecules and complex spatial configuration. In the present work, we systematically reviewed the structures and pharmacological activities of macrolides from cyanobacteria. Our data would help establish an effective support system for the discovery and development of cyanobacterium-derived macrolides.Entities:
Keywords: bioactivity; cyanobacteria; macrolides; secondary metabolites
Mesh:
Substances:
Year: 2017 PMID: 28445442 PMCID: PMC5450532 DOI: 10.3390/md15050126
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Anti-neoplastic profiling results for cyanobacterium-derived macrolides on different cell lines. Data are represented as IC50 [log(μM)].
Anti-neoplastic property of cyanobacterium-derived macrolides on different cell lines.
| Metabolite | Source | Location | Target Cell Lines | Concentration/Effect | Reference |
|---|---|---|---|---|---|
| lyngbyabellin A ( | Guam | KB cells and LoVo cells | IC50 value of 0.03 and 0.50 µg/mL respectively | [ | |
| lyngbyabellin B ( | Guam | KB cells and LoVo cells | IC50 value of 0.10 and 0.83 µg/mL respectively | [ | |
| lyngbyabellin E ( | Papua New Guinea | NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells | LC50 value of 0.4 and 1.2 µM respectively | [ | |
| lyngbyabellin F ( | Papua New Guinea | NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells | LC50 value of 1.0 and 1.8 µM respectively | [ | |
| lyngbyabellin G ( | Papua New Guinea | NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells | LC50 value of 2.2 and 4.8 µM respectively | [ | |
| lyngbyabellin H ( | Papua New Guinea | NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells | LC50 value of 0.2 and 1.4 µM respectively | [ | |
| lyngbyabellin I ( | Papua New Guinea | NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells | LC50 value of 1.0 and 0.7 µM respectively | [ | |
| lyngbyabellin N ( | Palmyra Atoll, USA | H-460 human lung carcinoma and HCT116 colon cancer cell lines | IC50 value of 0.0048–1.8 µM and 15 µM respectively | [ | |
| lyngbyaloside B ( | Palau | KB cells and LoVo cells | IC50 value of 4.3 and 15 µM respectively | [ | |
| 2- | Apra Harbor, Guam | HT29 colorectal adenocarcinoma and HeLa cells | IC50 value of 38 and 33 µM respectively | [ | |
| 18 | Apra Harbor, Guam | HT29 colorectal adenocarcinoma and HeLa cells | IC50 value of 13 and 9.3 µM respectively | [ | |
| 18 | Apra Harbor, Guam | HT29 colorectal adenocarcinoma and HeLa cells | IC50 value of >100 µM and 53 µM respectively | [ | |
| biselyngbyaside ( | Tokunoshima Island, Japan | HeLa S3 cells | IC50 value of 0.1 μg/mL | [ | |
| biselyngbyaside B ( | Tokunoshima Island, Japan | HeLa S3 cells and HL60 cells | IC50 value of 3.5 and 0.82 µM respectively | [ | |
| biselyngbyaside E ( | Ishigaki Island, Japan | HeLa and HL60 cells | IC50 value of 0.19 and 0.071 µM respectively | [ | |
| biselyngbyaside F ( | Ishigaki Island, Japan | HeLa and HL60 cells | IC50 value of 3.1 and 0.66 µM respectively | [ | |
| biselyngbyolide A ( | Tokunoshima Island, Japan | HeLa S3 cells and HL60 cells | IC50 value of 0.22 and 0.027 µM respectively | [ | |
| biselyngbyolide B ( | Ishigaki Island, Japan | HeLa S3 cells and HL60 cells | IC50 value of 0.028 and 0.0027 µM respectively | [ | |
| caylobolide A ( | Bahamian | human colon tumor cells HCT 116 | IC50 values of 9.9 µM | [ | |
| caylobolide B ( | Florida USA | HT29 colorectal adenocarcinoma and HeLa cervical carcinoma cells | IC50 value of 4.5 and 12.2 µM respectively | [ | |
| swinholide A ( | Fiji | several cancer cell lines | IC50 values of 0.37 nM–1.0 µM | [ | |
| ankaraholide A ( | Madagascar | NCI-H460, Neuro-2a cells and MDA-MB-435 cells | IC50 value of 119, 262 and 8.9 nM respectively | [ | |
| scytophycin A ( | Oahu, Hawaii | human carcinoma of nasopharynx Cell (KB cells) | IC50 value of 1 ng/mL | [ | |
| scytophycin B ( | Oahu, Hawaii | KB cells | IC50 value of 1 ng/mL | [ | |
| scytophycins C-E ( | Oahu, Hawaii | KB cells | IC50 value of 10–100 ng/mL | [ | |
| 6-hydroxyscytophycin B ( | cultured | KB cells and LoVo cells | MICs of 1–5 and 10–50 ng/mL respectively | [ | |
| 19- | cultured | KB cells and LoVo cells | MICs of 1–5 and 10–50 ng/mL respectively | [ | |
| 6-hydroxy-7- | cultured | KB cells and LoVo cells | MICs of 1–5 and 10–50 ng/mL respectively | [ | |
| tolytoxin ( | Fanning Island | KB cells and LoVo cells | IC50 value of 8.4 and 5.3 nM respectively | [ | |
| debromoaplysiatoxin ( | Marshall Islands | P-388 lymphocytic mouse leukemia | weak | [ | |
| lyngbouilloside ( | Papua New Guinea | neuroblastoma cells | IC50 value of 17 µM | [ | |
| koshikalide ( | Mie Prefecture | HeLa S3 cells | IC50 value of 42 µg/mL | [ | |
| sanctolide A ( | cultured | HT-29 and MDA-MB-435 cell lines | nd a | [ | |
| acutiphycin ( | Manoa Valley Oahu, Hawaii | KB cells and NIH/3T3 cells | ED50 < 1 µg/mL | [ | |
| 20,21-didehydroacutiphycin ( | Manoa Valley Oahu, Hawaii | KB cells and NIH/3T3 cells | ED50 < 1 µg/mL | [ | |
| polycavernoside D ( | Puerto Rican | H-460 human lung cancer cell lines | EC50 value of 2.5 µM | [ | |
| bastimolide A ( | Panama | Vero cells | IC50 value of 2.1 µM | [ | |
| nuiapolide ( | colonial cyanobacterium (071905-NII-01) | Hawaii | Jurkat cells and cancerous T lymphocytes | anti-chemotactic activity | [ |
Not determined.
Figure 2Chemical structures of Compounds 1–11.
Figure 3Chemical structures of Compounds 12–16.
Figure 4Chemical structures of Compounds 17–24.
Figure 5Chemical structures of Compounds 25 and 26.
Figure 6Chemical structures of Compounds 27–29.
Figure 7Chemical structures of Compounds 30–38.
Figure 8Chemical structures of Compounds 39–46.
Figure 9Chemical structures of Compounds 47–51.
Antibacterial and antifungal macrolides.
| Metabolite | Source | Location | Target | Concentration/Effect | Reference |
|---|---|---|---|---|---|
| 6-hydroxyscytophycin B ( | cultured | Fungus (1) | nd a | [ | |
| 19- | cultured | Fungus (1) | nd a | [ | |
| 6-hydroxy-7- | cultured | Fungus (1) | nd a | [ | |
| tolytoxin ( | Fanning Island | Fungi | MIC value of 0.25 nM respectively | [ | |
| 7-OMe-scytophycin B ( | cultured | Fungus | MIC values of 0.40 and 0.80 mM respectively; IC50 value of 0.19 and 0.23 µM respectively | [ | |
| amantelide A ( | Oscillatoriales | Guam | Fungi | totally inhibited of 62.5 μg/mL | [ |
| amantelide B ( | Oscillatoriales | Guam | Fungus | totally inhibited of 6.25 μg/mL | [ |
Not determined.
Figure 10Chemical structures of Compounds 52–54.
Effects of cyanobacterium-derived macrolides on animals.
| Metabolite | Source | Location | Target Fauna | Impacts | Reference |
|---|---|---|---|---|---|
| lyngbyabellin A ( | Guam | mice | LD50 value of 1.2–1.5 mg/kg | [ | |
| tolytoxin ( | cultured | mice | LD50 value of 1.5 mg/kg | [ | |
| sanctolide A ( | cultured | brine shrimp | LD50 value of 23.5 μM | [ | |
| gloeolactone ( | Clark Canyon Reservoir | brine shrimp | 100% killed at 125 µg/mL | [ | |
| phormidolide ( | Sulawesi, Indonesia | brine shrimp | LD50 value of 1.5 μM | [ | |
| cyanolide A ( | Papua New Guinea | snail vector | LD50 value of 1.2 μM | [ |
Figure 11Chemical structures of Compounds 55–57.
Other bioactivity of cyanobacterium-derived macrolides.
| Metabolite | Source | Location | Biological Activity | Reference |
|---|---|---|---|---|
| biselyngbyaside ( | Okinawa Prefecture Japan | osteoclast differentiation and function | [ | |
| debromoaplysiatoxin ( | Enewetak Atoll, Marshall Islands | produce an irritant pustular folliculitis in humans and cause a severe cutaneous inflammatory reaction in the rabbit and in hairless mice | [ | |
| bastimolide A ( | Caribbean coast of Panama | [ | ||
| malyngolide dimer ( | Panama | [ | ||
| tanikolide dimer ( | Madagascar | SIRT2 (IC50 = 176 nM to 2.4 µM) | [ | |
| palmyrolide A ( | Palmyra Atoll | suppression of calcium influx in cerebrocortical neurons (IC50 value of 3.70 µM) sodium channel blocking activity in neuro-2a cells (IC50 value of 5.2 µM) | [ | |
| cocosolide ( | Guam | inhibition of IL-2 production and T-cell proliferation | [ |
Figure 12Chemical structures of Compounds 58–64.